Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes

European Journal of Clinical Pharmacology

Volumn 56, Issue 12, 2001, Pages 881-888

  Facciolá, Gabriella ^a   Hidestrand, Mats ^b   Von Bahr, Christer ^c   Tybring, Gunnel ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

CYP1A2; Cytochrome P450; Melatonin metabolism

Indexed keywords

6 HYDROXYMELATONIN; 6-HYDROXYMELATONIN; CYTOCHROME P450; DRUG DERIVATIVE; FLUVOXAMINE; ISOENZYME; MELATONIN; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CELL CULTURE; DRUG EFFECT; ENZYME SPECIFICITY; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYLATION; LIVER MICROSOME; METABOLISM; PHYSIOLOGY;

CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FLUVOXAMINE; HUMANS; HYDROXYLATION; ISOENZYMES; MELATONIN; MICROSOMES, LIVER; SEROTONIN UPTAKE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 0035293495     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000245     Document Type: Article

References (41)

1. Andersson T, Regårdh CG, Dahl-Puustinen MJ, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12: 415-416
2. Arendt J (1988) Melatonin. Clin Endocrinol 29: 205-229
3. Bonn D (1996) Melatonin's multifarious marvels: miracle or myth? Lancet 347: 184
4. Bourrié M, Meunier V, Berger Y, Fahre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277: 321-332
5. Brøsen K, Skjelbo E, Rasmussen BB, Poulson HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214
6. Brzezinski A (1997) Melatonin in humans. N Engl J Med 336: 186-195
7. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS (2000) The absolute bioavailability of oral melatonin. J Clin Pharmacol 40: 781-784
8. Di WL, Kadva A, Johnston A, Silman R (1997) Variable bioavailability of oral melatonin. N Engl J Med 336: 1028-1029
9. Di WL, Djahanbakhch O, Kadva A, Street C, Silman R (1999) The pineal and extra-pineal origins of 5-sulphatoxy N-acetyl-serolonin in humans. J Pineal Res 26: 221-226
10. Funck-Brentano C, Becquemont L, Lenevu A, Roux A, Jaillon P, Beaune P (1997) Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 280: 730-738
11. Härtter S, Grözinger M, Weigamnn H, Röschke J, Hiemke C (2000) Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 67: 1-6
12. Jeppesen U, Skjelbo E, Rasmussen B, Poulsen HE, Loft S (1997) Fluvoxamine inhibits the CYP2C19 catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 62: 279-286
13. Kalow W, Tang B-K (1991) Use of caffeine metabolic ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50: 508-519
14. Kato R, Yamazoe Y (1994) The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 4: 359-362
15. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, Kuroiwa Y (1997) Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 280: 927-933
16. Krynetski EY, Drutsa VL, Kovaleva IE, Luzicov VN (1995) High yield expression of functionally active human liver CYP2D6 in yeast cells. Pharmacogenetics 5: 103-109
17. Lane EA, Moss HB (1985) Pharmacokinetics of melatonin in man1: first pass hepatic metabolism. J Clin Endocrinol Metab 61: 1214-1216
18. Leone RM, Silman RE (1984) Melatonin can be differentially metabolized in the rat to produce N-acetylserotonin in addition to 6-hydroxy-melatonin. Endocrinology 114: 1825-1832
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275
20. Miners JO, Birkett DJ (1998). Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45: 525-538
21. Newton DJ, Wang RW, Lu A (1995) Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23: 154-158
22. Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M (1997) A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 52: 1034-1040
23. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M (1994) Inhibition of diazepam metabolism by fluvoxamine: a pharmakinetic study in normal volunteers. Clin Pharmacol Ther 56: 471-476
24. Petrie K, Dawson AG, Thompson L, Brook R (1993) A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol Psychiatry 33: 526-530
25. Rasmussen BB, Nielsen TL, Brøsen K (1998) Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 83: 240-245
26. Reiter RJ (1995) The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage. Neurochem Int 27: 453-460
27. Sack RL, Hughes RJ, Edgar DM, Lewy AJ (1997) Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep 20: 908-915
28. Schmider J, Greenblatt DJ, Harmatz JS, Shader R (1996) Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. Br J Clin Pharmacol 41: 593-604
29. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI (1997) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin para-hydroxylation. Br J Clin Pharmacol 44: 495-498
30. Skene DJ, Bojkowski CJ, Arendt J (1994) Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J clin Pharmacol 37: 181-186
31. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ (1993a) Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1: 57-60
32. Tan DX, Poeggeler B, Reiter RJ, Chen LD, Chen S, Manchester LC, Barlow-Walden LR (1993b) The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett 70: 65-71
33. Tjia JF, Colbert J, Back DJ (1996) Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 276: 912-917
34. Truan G, Cullin C, Reisdorf P, Urban P, Pompon D (1993) Enhanced in vivo monooxygenase activities of mammalian P450s in engineered yeast cells producing high levels of NADPH-P450 reductase and human cytochrome b5. Gene 125: 49-55
35. von Bahr C, Groth CG, Jansson H, Lundgren G, Lind M, Glauman H (1980) Drug metabolism in human liver in vitro: establishment of a liver bank. Clin Pharmacol Ther 27: 711-725
36. von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Röjdmark S (2000) Fluvoxamine, but not citalopram, increases serum melatonin in healthy subjects. Eur J Clin Pharmacol 56: 123-127
37. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RJ (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitors antidepressant. J Clin Psychopharmacol 15: 125-131
38. Waldhauser F, Waldhauser M, Lieberman HR, Deng M-H, Lynch HJ, Wurtman RJ (1984) Unavailability of oral melatonin in humans. Neuroendocrinology 39: 307-313
39. Wilkinson GR, Guengerich FP, Branch RA. (1992) Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Perganom Press, New York, pp 657-685
40. Wolfler A, Abuja PM, Schauenstein K, Liebmann PM (1999) N-acetylserotonin is a better extra- and intracellular antioxidant than melatonin. FEBS Lett 449: 206-210
41. Xu Z-H, Xie H-G, Zhou H-H (1996) In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 42: 518-521